Core Viewpoint - Huagu Green Biological (300970.SZ) forecasts a net profit of 100 million to 130 million yuan for the year 2025, a significant recovery from a loss of 47.57 million yuan in the previous year, driven by simultaneous increases in sales price and volume [2] Company Performance - The expected profit increase is attributed to the recovery of the edible mushroom industry, which has stabilized and improved market conditions in the second half of 2025, leading to a rise in product prices [2] - The company's expansion of production capacity has contributed to an increase in sales volume, further enhancing overall profitability [2] - The combination of improved sales prices and increased sales volume has resulted in a higher gross margin for the company [2]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日（以下简称"本 报告期""报告期"）。 证券代码：300970 证券简称：华绿生物 公告编号：2026-004 江苏华绿生物科技集团股份有限公司 2025 年度业绩预告 （二）业绩预告情况：亏损 扭亏为盈 同向上升 同向下降 | 项 目 | 本报告期 | 上年同期 | | | --- | --- | --- | --- | | 营业收入 | 120,000.00～140,000.00 万元 | 103,211.16 | 万元 | | | 比上年同期增长：16.27%～35.64% | | | | 归属于上市 | 盈利：10,000.00～13,000.00 万元 | 亏损：4,756.56 | 万元 | | 净利润 | 比上年同期上升：310.24%～373.31% | | | | 归属于上市 公司股东扣 除非经常性 | 万元 盈利：10,000.00～13,000.00 | 亏损：4,848.39 | 万 ...

Core Viewpoint - The company, Hualv Biotechnology, plans to acquire 100% equity of Queshan Huayuan Biotechnology Co., Ltd. from the Queshan County Finance Bureau, aiming to secure long-term operational stability and enhance investment outcomes in Queshan County [1] Group 1: Acquisition Details - The acquisition will be based on the total investment amount of approximately 239 million yuan, which includes main engineering, ancillary works, equipment, and supervision fees [1] - The payment for the acquisition will be made in installments: 50% within five working days after signing the formal equity transfer agreement, 40% within ten working days after completing the industrial and commercial change registration, and the remaining 10% as a performance guarantee within twelve months after the equity transfer [1] Group 2: Project Background - Queshan Huayuan is a platform company designated by the Queshan County People's Government and is wholly owned by the Queshan County Finance Bureau [1] - The first mushroom factory constructed by Queshan Huayuan has been completed and handed over to Hualv Biotechnology, with the factory's operational status meeting the company's expectations [1]

Core Viewpoint - The company, Hualv Biotechnology, is advancing its investment project in Queshan County, with plans to solidify its partnership with local government through a share acquisition framework agreement [1] Group 1: Project Overview - The company announced plans to establish a subsidiary in Queshan County, covering an area of approximately 500 acres with a total investment of around RMB 500 million [1] - The initial phase includes the construction of two edible mushroom factories, with land and facilities funded by the government [1] Group 2: Current Status and Future Plans - The first factory in Queshan County has been completed and is operational, achieving expected benefits [1] - To ensure long-term stability and reduce project risks, the company intends to sign a share acquisition framework agreement with relevant parties [1] Group 3: Strategic Agreements - The framework agreement aims to outline the future acquisition of 100% equity of a target company held by the Queshan Finance Bureau, including overall arrangements, prerequisites, and key terms [1] - This agreement is designed to enhance investment confidence and solidify existing cooperation outcomes [1]

Core Viewpoint - The company plans to sign an investment agreement with the People's Government of Que County to establish a new factory for the production of deer antler mushrooms, with a total investment of approximately RMB 300 million [1] Group 1: Project Details - The new factory will have an annual production capacity of 50,000 tons of deer antler mushrooms [1] - The project will cover an area of approximately 200 acres [1] - The investment proposal was approved during the company's fifth board meeting on January 16, 2026 [1] Group 2: Regulatory Compliance - The investment does not require submission for shareholder approval according to the Shenzhen Stock Exchange's Growth Enterprise Market listing rules and the company's articles of association [1]

证券代码：300970 证券简称：华绿生物 公告编号：2026-001 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、董事会召开情况 江苏华绿生物科技集团股份有限公司（以下简称"公司"）第五届董事会第 十七次会议于 2026 年 1 月 16 日以现场和通讯相结合的方式在公司二楼会议室召 开，会议通知于 2026 年 1 月 12 日以通讯方式向全体董事发出。会议由董事长余 养朝先生召集并主持，会议应出席董事 9 人，实际出席董事 9 人，公司高级管理 人员列席了本次会议。本次董事会的召开符合《中华人民共和国公司法》等有关 法律、行政法规等规范性文件及《公司章程》的规定。 二、董事会审议情况 经与会董事认真审议，形成如下决议： （一）审议通过了《关于拟签订<股权收购框架协议>的议案》 具体内容详见公司同日于巨潮资讯网（http://www.cninfo.com.cn）披露的《关 于拟签订<股权收购框架协议>的公告》（公告编号：2026-002）。 江苏华绿生物科技集团股份有限公司 第五届董事会第十七次会议决议公告 具体内容详见公司同日于巨潮资讯网（ht ...

关于拟签订《股权收购框架协议》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 证券代码：300970 证券简称：华绿生物 公告编号：2026-002 江苏华绿生物科技集团股份有限公司 特别提示： 1、江苏华绿生物科技集团股份有限公司（以下简称"公司"）于 2022 年 11 月 23 日披露了《关于签署〈投资协议〉并拟在确山县设立子公司的公告》（公 告编号：2022-064）。根据原计划，项目占地面积约 500 亩，预计总投资约人民 币 5 亿元，初期拟建设两个食用菌工厂。相关土地、大棚房及附属设施由政府方 出资购置或建设，待建设完成并取得合法手续后租赁给公司使用。租赁期满后， 若公司符合约定条件，可享有优先购买权。 目前，公司在确山县投资的第一个工厂已建成投产并实现预期效益。为保证 项目长期稳定，减少项目变动风险，公司拟与相关方签订《股权收购框架协议》， 明确收购政府投资资产的核心安排，以进一步巩固现有合作成果，增强当地产业 发展信心。 2、根据《深圳证券交易所创业板股票上市规则》等规范性文件及《江苏华 绿生物科技集团股份有限公司章程》（以下简称" ...

证券代码：300970 证券简称：华绿生物 公告编号：2026-003 江苏华绿生物科技集团股份有限公司 关于拟签订《投资协议》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 特别提示： 1、《投资协议》中关于项目投资金额、用地面积等指标均为预估数值，并 不代表对投资者的承诺。 2、根据《深圳证券交易所创业板股票上市规则》等规范性文件及《江苏华 绿生物科技集团股份有限公司章程》（以下简称"《公司章程》"）规定，本事 项无需提交公司股东会审议。 3、本次投资不构成关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。 4、公司于 2022 年 11 月 23 日在巨潮资讯网（http://www.cninfo.com.cn）披 露了《关于签署<投资协议>并拟在确山县设立子公司的公告》（公告编号： 2022-064），项目规划占地面积约 500 亩，项目预计总投资约人民币 5 亿元，初 期计划建设两个食用菌工厂，项目的土地、大棚房及其附属设施由政府方出资购 买或者建设，在约定时间完成建设并办理合法合规手续后租赁给公司。现第一个 工厂（金 ...

Market Overview - The planting industry sector declined by 0.42% on January 14, with Shennong Agricultural leading the decline [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index closed at 14248.6, up 0.56% [1] Individual Stock Performance - Hualu Biological (300970) saw a price increase of 4.06%, closing at 22.53 with a trading volume of 108,000 shares and a transaction value of 236 million yuan [1] - Hainan Rubber (601118) increased by 1.18%, closing at 5.98 with a trading volume of 1,009,400 shares and a transaction value of 609 million yuan [1] - Shennong Agricultural (300189) experienced a significant decline of 3.77%, closing at 6.89 with a trading volume of 2,088,600 shares and a transaction value of 1.454 billion yuan [2] Capital Flow Analysis - The planting industry sector experienced a net outflow of 243 million yuan from main funds, while retail investors saw a net inflow of 240 million yuan [2] - Notable net inflows from retail investors were observed in stocks like Hualu Biological and Hainan Rubber, while Shennong Agricultural faced significant outflows [3]

Group 1 - The core point of the news is that Hualu Bio has seen a stock price increase of 5.08%, reaching 22.75 CNY per share, with a trading volume of 190 million CNY and a turnover rate of 9.17%, resulting in a total market capitalization of 2.789 billion CNY [1] - Hualu Bio, established on June 8, 2010, and listed on April 12, 2021, specializes in the research, industrial cultivation, and sales of edible mushrooms, with revenue composition of 70.73% from enoki mushrooms and 29.27% from king oyster mushrooms [1] Group 2 - Among the top ten circulating shareholders of Hualu Bio, the Noan Multi-Strategy Mixed A Fund (320016) has recently entered the list, holding 1.0993 million shares, which accounts for 1.17% of the circulating shares, with an estimated floating profit of approximately 1.2092 million CNY [2] - The Noan Multi-Strategy Mixed A Fund was established on August 9, 2011, with a current scale of 1.855 billion CNY, achieving a year-to-date return of 5.21%, ranking 2743 out of 8838 in its category, and an annual return of 88.18%, ranking 316 out of 8089 [2] Group 3 - The fund manager of Noan Multi-Strategy Mixed A is Kong Xianzheng, who has been in the position for 5 years and 50 days, managing a total fund asset size of 5.608 billion CNY, with the best fund return during his tenure being 93.39% and the worst being -16.74% [3]